March 2024 - BioMedWire (BMW)

ThursdayMar 28, 2024 9:45 am

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

Longeveron recently released its full-year results for the period ended December 31, 2023, and provided a corporate update The update outlined the company’s plans to prioritize the development of Lomecel-B(TM) in Hypoplastic Left Heart Syndrome (“HLHS”), a rare, pediatric congenital heart condition characterized by an underdeveloped left side of the heart Longeveron plans to complete the enrollment in the ELPIS II trial for HLHS in 2024 The company also reported that it is exploring opportunities to advance its Alzheimer’s disease program through potential partnerships or other sources of funding Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for…

ThursdayMar 28, 2024 9:00 am

Astrotech Corp. (NASDAQ: ASTC) and AgLAB Inc. Use Mass Spectrometer Technology to Significantly Enhance Hemp and Cannabis Production Yield and Profit

The cannabinoid market value in 2023 was $22.23 billion and is expected to grow at a CAGR of 15.3%, resulting in an estimated market value of $60.36 billion The global mass spectrometry market will reach $6.77 billion in 2024 and is expected to grow at a CAGR of 6.25%, reaching $9.17 billion by 2029. Astrotech and subsidiary AgLAB Inc. are using mass spectrometry to boost the profitable yield of hemp and cannabis production The United States has seen a rising awareness of the health and therapeutic benefits of cannabinoids, prompting an expected market increase of 15.3%, from $22.23 billion in…

WednesdayMar 27, 2024 10:00 am

Researchers Link Type 2 Diabetes to Heightened Alzheimer’s Risk

Scientists at Texas A&M University have found evidence suggesting that there may be a link between Alzheimer’s disease risk and type 2 diabetes. This is backed by data from a separate study, which found that roughly 81% of individuals living with Alzheimer’s disease also have type 2 diabetes. Alzheimer’s is a progressive brain disorder that affects memory, thinking and behavior. The disorder is also a common cause of dementia, accounting for at least 60% of dementia cases. The scientists believe it’s possible that a high-fat diet may increase inflammation levels in the body, which could in turn heighten the risk…

TuesdayMar 26, 2024 9:45 am

Astiva Health’s Innovative Strategies for Enhancing Senior Mobility and Independence

Astiva Health Inc. is pioneering transformative healthcare for seniors, with a focus on enhancing mobility and promoting independence. This innovative approach places a strong emphasis on seniors as active participants in their healthcare journey, representing a shift towards a more interactive and preventive model of care. Embracing Active Participation Central to Astiva Health's mission is empowering seniors to engage actively in their healthcare decisions, supporting their flourishing in later years. The CDC highlights physical activity's crucial role in preventing chronic diseases among seniors, noting that regular physical activity can significantly reduce health risks associated with inactivity (CDC, 2020). Tailored Exercise…

TuesdayMar 26, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MS

Clene’s recently released 2023 financial and operational updates highlight the company’s developments for the treatment of amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis CNM-Au8(R) functions as a neuroprotective and remyelinating therapy in neurodegenerative diseases Recent data from the randomized, double-blind, placebo-controlled HEALEY-ALS Platform Trial and its open-label extension, reported by Clene in December 2023, revealed encouraging outcomes on survival and delayed clinical worsening Clene recently provided perspectives on its achievements and the development path for CNM-Au8(R) during its participation in the 36th Annual ROTH Conference, which was held March 18-19, 2024 Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene…

MondayMar 25, 2024 10:00 am

New Study Leverages Real-World Data to Assess Differences in Parkinson’s Progression

Recent research assessed the differences in Parkinson’s disease progression between research populations and real-world data. Parkinson’s disease is a progressive disorder that affects the nervous system and body parts controlled by the nerves. Illness-modifying treatments haven’t been successful for Parkinson’s, with some therapies that have shown promise in trials failing at later stages. The primary challenge to developing illness-modifying treatments for this particular condition is the fact that molecular processes that drive pathogenesis haven’t been understood properly. Additionally, diverse ages on the condition’s onset and different progression patterns indicate heterogeneity. For their research, the scientists used Harvard Biomarkers studies and…

FridayMar 22, 2024 10:00 am

Gene Signature Could Predict NSC Lung Cancer Response to Immunotherapy

New research has found genes that could help forecast how non-small cell lung cancer may respond to a treatment combination of low-dose radiation and immunotherapy. The researchers explained that these genes could help identify tumors that were more likely to be destroyed by immunotherapies. Immunotherapies work by activating an individual’s immune system to fight the cancer. Despite saving numerous lives, however, only about 25% of patients respond to it. Being able to predict who could benefit from this new discovery and the underlying mechanism of action would greatly benefit patients who gain no benefit from other modes of treatment. For…

ThursdayMar 21, 2024 10:30 am

PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline to Address Unmet Needs in Autism Spectrum Disorder via Suramin Sodium

Autism (“ASD”) is a global problem, with no generally accepted treatment. In the UK alone, between 1998 and 2018, research has found a greater than 780% increase in the number of autism cases PaxMedica is focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of ASD and other serious conditions with intractable neurologic symptoms The ASD therapeutics market was valued at $2.01 billion in 2023 and is expected to reach $3.42 billion by 2030, growing at a CAGR of 7.9% There is currently no approved pharmacologic treatment targeting the cause and symptoms. Current treatments only address the…

WednesdayMar 20, 2024 11:00 am

How AI Can Help in Crafting Memorable eCommerce Experiences

The emergence of incredibly advanced artificial intelligence (AI)-powered tools in recent years has provided e-commerce businesses with an effective tool for creating memorable customer experiences. A growing number of consumers are buying goods online, thanks to the convenience, variety, better prices and safety offered by online marketplaces. Evolving consumer behavior in the wake of coronavirus-related lockdowns has also contributed to the increase in online shopping. With more businesses worldwide opening online stores, competition in the e-commerce space is heating up fast. Consequently, providing customers with a memorable and enjoyable shopping experience will be key for online retailers who want to…

MondayMar 18, 2024 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Welcomes Proven Commercialization Leader to Its Board of Directors

CNS Pharmaceuticals recently appointed Amy Mahery, a biotech commercialization leader, to its Board of Directors Ms. Mahery brings over 20 years’ experience, having worked with small and large companies, and has held diverse commercial leadership roles in the U.S. and globally The company believes Ms. Mahery’s guidance, insight, and vast pharma industry network will indeed be invaluable as the company advances Berubicin, its flagship drug candidate, toward completion of its global potentially pivotal clinical trial and potential regulatory approval The company recently completed the enrollment of patients in its potentially pivotal global clinical trial Ms. Mahery believes Berubicin represents an…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050

Month: March 2024

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

Astrotech Corp. (NASDAQ: ASTC) and AgLAB Inc. Use Mass Spectrometer Technology to Significantly Enhance Hemp and Cannabis Production Yield and Profit

Researchers Link Type 2 Diabetes to Heightened Alzheimer’s Risk

Astiva Health’s Innovative Strategies for Enhancing Senior Mobility and Independence

Clene Inc. (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MS

New Study Leverages Real-World Data to Assess Differences in Parkinson’s Progression

Gene Signature Could Predict NSC Lung Cancer Response to Immunotherapy

PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline to Address Unmet Needs in Autism Spectrum Disorder via Suramin Sodium

How AI Can Help in Crafting Memorable eCommerce Experiences

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Welcomes Proven Commercialization Leader to Its Board of Directors

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search